18 Marzo 2022
Marieke M B Seyger, Matthias Augustin, Michael Sticherling, Teresa Bachhuber, Juanzhi Fang, James Hetherington, James Lucas, Sophie Meakin, Craig Richardson, Amy S Paller

Physician-reported clinical unmet needs, burden and treatment patterns of paediatric psoriasis patients: A US and EU real-world evidence study

Acta Derm Venereol. 2022 Feb 28;102:adv0066

Key messages

  • Il presente studio è un’analisi retrospettiva dei dati raccolti dall’Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey.
  • Una percentuale considerevole di pazienti ha presentato una malattia moderata o severa e sintomi persistenti relativi alla psoriasi, con coinvolgimento di multiple aree corporee.
  • Una proporzione significativa di pazienti è stata sotto-trattata e ciò può spiegare l’alto impatto della malattia.


This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey.

Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively.

There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.

Tagged on:
Accedi all’abstract originale